Advertisement

Organisation › Details
BioNTech SE (Nasdaq: BNTX)
BioNTech SE is Europe’s largest privately-held biopharmaceutical company pioneering the development of precision immunotherapies for individualized treatment of cancer and prevention of infectious diseases. The company combines all building blocks for more precise and individualized immunotherapies under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based product candidates through innovative chimeric antigen receptors and T-cell receptor-based compounds to novel checkpoint immunomodulators and small molecules. BioNTech’s product development approach has been validated by seven corporate partnerships with, in chronological order, Genmab, Eli Lilly and Company, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant and Pfizer, and its scientific approach through over 60 peer-reviewed scientific publications. Founded in 2008, BioNTech’s financial shareholders include the Struengmann Family Office as its majority shareholder, Fidelity Management & Research Company, Invus, Janus Henderson Investors, MIG Fonds, Redmile Group, Salvia and several European family offices. *
![]() |
Start | 2019-05-08 reorganised before |
Group | BioNTech (Group) | |
![]() |
Industry | cancer immunotherapy (immuno-oncology, I-O) |
Industry 2 | cancer test | |
Street | 12 An der Goldgrube | |
City | 55131 Mainz | |
Address record changed: 2024-03-22 | ||
Basic data | Employees | G: 5,001 to 10,000 (2023-12-31) |
Currency | EUR | |
Annual sales | 3,819,000,000 (revenues, total, consolidated (2023) 2023-12-31) | |
Profit | 930,300,000 (2023-12-31) | |
Cash | 11,663,700,000 (2023-03-31) | |
* Document for »About Section«: BioNTech SE. (5/8/19). "Press Release: BioNTech Acquires MabVax Therapeutics’ Antibody Assets to Expand Portfolio". Mainz. | ||
Record changed: 2024-12-29 |
Advertisement

More documents for BioNTech (Group)
- [1] BioNTech SE. (2/8/24). "Press Release: BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs". Mainz & London....
- [2] CureVac N.V.. (12/19/23). "Press Release: CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE". Tübingen....
- [3] BioNTech SE. (7/31/23). "Press Release: BioNTech Completes Acquisition of InstaDeep". Mainz....
- [4] BioNTech SE. (1/10/23). "Press Release: BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development". Mainz & London....
- [5] BioNTech SE. (1/6/23). "Press Release: BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030". Mainz....
- [6] InstaDeep. (1/25/22). "Press Release: InstaDeep Raises $100M to Scale Decision-Making AI Products that Solve Real-World Problems". London....
- [7] BioNTech SE. (1/11/22). "Press Release: BioNTech and InstaDeep Developed and Successfully Tested Early Warning System to Detect Potential High-Risk SARS-CoV-2 Variants". Mainz & London....
- [8] BioNTech SE. (1/10/22). "Press Release: BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies". Mainz & Cambridge....
- [9] BioNTech SE. (11/25/20). "Press Release: BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel Immunotherapies". Mainz & London....
- [10] BioNTech SE. (7/20/20). "Press Release: Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2". New York, NY & Mainz....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top